1. Alpha-cyclodextrin increases glucagon-like peptide-1 secretion in multiple models and improves metabolic status in mice.
- Author
-
Smits MM, von Voss L, Drzazga AK, Beaman EE, Brethvad AO, Holst JJ, and Rosenkilde MM
- Subjects
- Animals, Mice, Male, Rats, Humans, Glucose Tolerance Test, Blood Glucose metabolism, Obesity metabolism, Obesity drug therapy, Obesity physiopathology, Insulin metabolism, Diet, High-Fat adverse effects, Glucagon-Like Peptide 1 metabolism, alpha-Cyclodextrins metabolism, alpha-Cyclodextrins chemistry, alpha-Cyclodextrins pharmacology, Mice, Inbred C57BL
- Abstract
Alpha-cyclodextrin (α-CD) is a non-absorbable and soluble fiber that causes weight loss. We studied whether this is due to an effect on GLP-1 secretion. In GLUTag cells, α-CD increased GLP-1 secretion up to 170% via adenylyl cyclase, phospholipase C, and L-type calcium channels dependent processes. In rat isolated colon perfusions, luminal α-CD increased GLP-1 secretion with 20%. In lean mice, once daily α-CD versus saline caused weight loss and lowered the peak in glucose after an oral glucose tolerance test (OGTT). In obese mice, α-CD added to high-fat diet caused weight loss similar to the control group (receiving cellulose). However, compared to cellulose, the α-CD group ate less. During an OGTT, no differences were observed in glucose, insulin and GLP-1. Thus, α-CD increases GLP-1 secretion in a dose-dependent manner and could be a safe and easy addition to food products to help reduce body weight., Competing Interests: Declaration of competing interest MMS, LV, AKD, EEB and AOB have nothing to disclose. MMR and JJH are cofounders and minority shareholders in Antag Therapeutics. JJH: Advisory boards: Novo Nordisk; Lecture fees: Novo Nordisk; Merck. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Mark Smits reports financial support was provided by Lundbeck Foundation. Jens Juul Holst reports a relationship with Novo Nordisk that includes: consulting or advisory and speaking and lecture fees. Jens Juul Holst reports a relationship with Merck & Co Inc. that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF